Sapreme is a preclinical-stage biotech company developing next-generation RNA therapeutics for patients with genetically driven diseases. Our proprietary endosomal escape technology enables targeted delivery of large molecules such as ASOs and siRNAs to intracellular targets in liver and extrahepatic tissues, such as muscle, heart and the brain.
With successful PoCs in rodents and non-human primates, Sapreme is now building a pipeline of therapeutic applications to address high unmet needs in neuromuscular, cardiometabolic diseases and beyond.
Our lead program is designed as a best-in-class therapy for Duchenne muscular dystrophy, an incurable and fatal pediatric monogenic disease. In addition, we are pursuing strategic partnerships to co-develop products with select pharma/biotech companies.
